Improved cough- and sputum-related quality of life after initiation of treatment in pulmonary tuberculosis.
Adult
Age Factors
Aged
Aged, 80 and over
Antitubercular Agents
/ administration & dosage
Cough
/ therapy
Drug Combinations
Female
Humans
Male
Middle Aged
Prospective Studies
Quality of Life
Regression Analysis
Severity of Illness Index
Sputum
Surveys and Questionnaires
Treatment Outcome
Tuberculosis, Pulmonary
/ drug therapy
Young Adult
Bronchial tuberculosis
Cavitary lesion
Cough and Sputum Assessment Questionnaire
Leicester Cough Questionnaire
Journal
Respiratory investigation
ISSN: 2212-5353
Titre abrégé: Respir Investig
Pays: Netherlands
ID NLM: 101581124
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
01
11
2018
revised:
25
12
2018
accepted:
09
01
2019
pubmed:
11
2
2019
medline:
18
12
2019
entrez:
11
2
2019
Statut:
ppublish
Résumé
Cough and sputum are the major symptoms of pulmonary tuberculosis (TB). However, the relationship between these symptoms and treatment for TB is not fully understood. The aim of this prospective study was to clarify the cough- and sputum-related quality of life (QOL) in patients with pulmonary TB before and after initiation of treatment. The study included 85 patients with active pulmonary TB who were hospitalized from July 2014 to August 2015. They completed the Leicester Cough Questionnaire (LCQ: range 3-21, the higher the better) and the Cough and Sputum Assessment Questionnaire (CASA-Q: range 0-100, the higher the better) on admission and at discharge after 2 months of treatment. The LCQ and CASA-Q scores were reduced on admission. A multivariate linear regression analysis revealed that younger age, more than two cavitary lesions, and the presence of bronchial TB were associated with reduced LCQ total score. However, each score significantly improved at discharge, regardless of the initial grade of the sputum smear, site of the lesion, number of cavitary lesions, and presence of bronchial TB. The change in the mean LCQ total score was 2.28 (95% confidence interval, 1.56-3.00). The changes in the mean CASA-Q cough symptoms, cough impact, sputum symptoms, and sputum impact scores were 22.84 (18.44-27.25), 10.96 (7.20-14.71), 17.25 (13.33-21.18), and 5.25 (2.49-8.00), respectively. Cough- and sputum-related QOL was impaired in patients with pulmonary TB before treatment but improved after initiation of treatment regardless of the clinical characteristics.
Sections du résumé
BACKGROUND
BACKGROUND
Cough and sputum are the major symptoms of pulmonary tuberculosis (TB). However, the relationship between these symptoms and treatment for TB is not fully understood. The aim of this prospective study was to clarify the cough- and sputum-related quality of life (QOL) in patients with pulmonary TB before and after initiation of treatment.
METHODS
METHODS
The study included 85 patients with active pulmonary TB who were hospitalized from July 2014 to August 2015. They completed the Leicester Cough Questionnaire (LCQ: range 3-21, the higher the better) and the Cough and Sputum Assessment Questionnaire (CASA-Q: range 0-100, the higher the better) on admission and at discharge after 2 months of treatment.
RESULTS
RESULTS
The LCQ and CASA-Q scores were reduced on admission. A multivariate linear regression analysis revealed that younger age, more than two cavitary lesions, and the presence of bronchial TB were associated with reduced LCQ total score. However, each score significantly improved at discharge, regardless of the initial grade of the sputum smear, site of the lesion, number of cavitary lesions, and presence of bronchial TB. The change in the mean LCQ total score was 2.28 (95% confidence interval, 1.56-3.00). The changes in the mean CASA-Q cough symptoms, cough impact, sputum symptoms, and sputum impact scores were 22.84 (18.44-27.25), 10.96 (7.20-14.71), 17.25 (13.33-21.18), and 5.25 (2.49-8.00), respectively.
CONCLUSIONS
CONCLUSIONS
Cough- and sputum-related QOL was impaired in patients with pulmonary TB before treatment but improved after initiation of treatment regardless of the clinical characteristics.
Identifiants
pubmed: 30738923
pii: S2212-5345(18)30289-2
doi: 10.1016/j.resinv.2019.01.002
pii:
doi:
Substances chimiques
Antitubercular Agents
0
Drug Combinations
0
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
252-259Informations de copyright
Copyright © 2019 The Japanese Respiratory Society. Published by Elsevier B.V. All rights reserved.